Influence of radiation therapy on the outcome of T1-2N0M0 triple-negative breast cancer: A SEER population-based retrospective analysis.

Authors

null

Xiaoxiang Guan

Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Xiaoxiang Guan , Huan Li , Yajuan Chen , Xin Wang , Lin Tang , Yucai Wang , Yongqian Shu

Organizations

Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Jinling Hospital, Southern Medical University, Nanjing, China, Jinling Hospital,Nanjing Medical University, Nanjing, China, Medical School of Nanjing University, Nanjing, China, Mayo Clinic, Rochester, MN, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, P.R. China, Nanjing, China

Research Funding

Other

Background: For T1-2N0M0 breast cancer after surgery and axillary staging, the current NCCN guideline recommends radiation therapy (RT) after lumpectomy but not total mastectomy unless there is a positive or less than 1 mm negative margin. This recommendation is regardless of hormonal status. Triple-negative breast cancer is a generally considered more aggressive compared with hormone positive breast cancer. We sought to investigate whether there is a survival benefit of RT in T1-2N0M0 TNBC. Methods: A Population-based retrospective analysis was performed using the Surveillance, Epidemiology, and End Results (SEER) database. Patients included in the analysis were divided into three groups according to surgery modality and RT: breast conservation therapy (BCT, i.e., lumpectomy + RT), mastectomy alone, and mastectomy + RT. The survival endpoints were breast cancer-specific survival (BCSS) and overall survival (OS), and survival analysis was performed using the Kaplan-Meier method. Results: A total of 22473 female with T1-2N0M0 TNBC diagnosed between 2010 and 2015 were included, with 13395 (60%) T1 and 9078 (40%) T2 cases. Surgery, RT and chemotherapy was done in 21674 (96%), 9633 (43%) and 14651 (65%) patients, respectively. Patients who underwent RT were older ( > 50 years, 78% vs 72%, P< 0.001), had fewer T2 (35% vs 44%, P< 0.001) tumor, and had more chemotherapy utilization (72% vs 60%, P< 0.001). 8807 patients had BCT; 8329 had mastectomy alone and 635 had mastectomy + RT. The 5-year BCSS rate was 94.3% for BCT, 93.3% for mastectomy alone (P= 0.009 vs BCT), and 83.7% for mastectomy + RT (P< 0.001 vs BCT and P< 0.001 vs mastectomy alone), respectively. The 5-year OS rate was 88.6% for BCT, 83.0 % for mastectomy alone (P< 0.001 vs BCT), and 79.6% for mastectomy + RT (P< 0.001 vs BCT and P= 0.190 vs mastectomy alone), respectively. Conclusions: In patients with T1-2N0M0 TNBC, BCT was associated with superior BCSS and OS compared to mastectomy with or without RT. After mastectomy, there was no evidence of survival benefit of RT, with worse BCSS and similar OS.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Local-Regional Therapy

Citation

J Clin Oncol 37, 2019 (suppl; abstr e12073)

DOI

10.1200/JCO.2019.37.15_suppl.e12073

Abstract #

e12073

Abstract Disclosures

Similar Abstracts

First Author: Judith Pérez-Granado

First Author: Yicong Chen

First Author: Prantik Das

First Author: Katarzyna Joanna Jerzak